Publish date:

Monday's Headliners: Citigroup

The financial-services giant will release its earnings, as will Genentech and Mattel.

The full force of earnings season is just around the corner, and investors will be greeted Monday, Oct. 15, with quarterly results from the financial space and a big name in biotechnology.


(C) - Get Report

, who has already warned that its third-quarter profit would plunge 60% from a year ago, primarily because of a $3.3 billion hit tied to writedowns, is scheduled to report ahead of the open.

Also set for the early part of the day are online broker

Charles Schwab

(SCHW) - Get Report

and toymaker


(MAT) - Get Report

, who was marred by product recalls in recent weeks.

Following the close, biotech giant



is due to report, and one of the crucial details will be the growth for its cancer drug Avastin.

Only a handful of economic reports will be released in the coming week, and just one is expected on the first day, the New York Empire State Index.

As for the upcoming articles on

TheStreet Recommends

, staff reporter Laurie Kulikowski says this is a key quarter for the nation's big banks as she previews their earnings. The late-summer subprime meltdown and credit crunch has already led to billions in writedowns, and more are sure to come.

One name investors must watch closely, she says, is



JPMorgan Chase

(JPM) - Get Report


Also, find out how Ken Heebner's

(CGMFX) - Get Report

CGM Focus fund has gained a staggering 40% over the past two months. Columnist Brett Arends examines the well-known fund manager's strategy and provides some insight as to what's driving this stellar performance. Individual investors might be able to learn a thing or two.

Meanwhile, senior writer Melissa Davis will take a closer look at the goings-on at nursing home operator

Sunrise Senior Living


as the company gears up for a proxy fight, and staff reporter Simon Constable gets to the bottom of what's going on at the

(SGGDX) - Get Report

First Eagle Gold fund, which has lost a manager for the second time this year. The first one vanished without a trace, and now his replacement is leaving over a dispute about the fund's investment strategy.